Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

Abstract

In treatment-naive participants, RPV/FTC/TDF demonstrated noninferior efficacy and improved tolerability compared with EFV/FTC/TDF, as well as a statistically significant difference in efficacy for participants with baseline HIV-1 RNA 100000 copies/ml or less at week 48.

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU

“…Improvements from baseline in CD4? cell count did not significantly differ between the two regimens at either timepoint [11,12], and although the rate of virological failure was 1.4-and 1.6-fold higher with the rilpivirine-than with the efavirenzbased regimen at 48 [11] and 96 weeks [12], the betweengroup difference was reported as not significant at week 48 [11] (Table 2). These findings are generally supported by a pooled subset analysis of two earlier trials (ECHO and THRIVE) in patients who received rilpivirine or efavirenz in combination with emtricitabine/tenofovir DF (Table 2) [8,13,14].…”

“…However, in some instances, virological outcomes were slightly more favourable with the efavirenz-than rilpivirine-based regimen among patients with high viral loads ([100,000 copies/mL) or low CD4? cell counts (B200 or B350 cells/ lL) [11,12], although between-group differences were not significant where reported [11].…”

“…cell count of[350 cells/ lL or a viral load of B100,000 copies/mL at baseline achieved a response with emtricitabine/rilpivirine/tenofovir DF than with emtricitabine/efavirenz/tenofovir DF at 48 and/or 96 weeks; notably patients with baseline CD4? cell counts of [350 or [200 cells/lL or viral loads of B100,000 copies/mL generally had the highest virological response rates and the lowest virological failure rates with emtricitabine/rilpivirine/tenofovir DF [11,12,20]. However, in some instances, virological outcomes were slightly more favourable with the efavirenz-than rilpivirine-based regimen among patients with high viral loads ([100,000 copies/mL) or low CD4?…”

“…The emtricitabine/rilpivirine/tenofovir DF single-tablet regimen was noninferior to the emtricitabine/efavirenz/ tenofovir DF single-tablet regimen in establishing virological suppression, as measured by the proportion of patients who achieved a viral load of \50 copies/mL after 48 (primary endpoint) [11] or 96 [12] weeks of treatment in the STaR trial (Table 2). Improvements from baseline in CD4?…”

An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection

“…Also it completely lacks uritine-5=-diphosphoglucuronyl transferase as well as cytochrome P450 enzyme inhibition ability (20). The antiretroviral efficacy of FTC for treating both naive and experienced patients has been demonstrated in clinical trials (21,22). Thus, FTC is one of the most common drugs in the various cARV drug combinations that have shown synergistic inhibition of HIV-1.…”